Rocklatan for Glaucoma

Age: 18+

Sex: Any

Trial Phase: Phase 4

Sponsor: Mayo Clinic

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).

Who Is on the Research Team?

Arthur J Sit, MD, MS

Principal Investigator

Mayo Clinic

Are You a Good Fit for This Trial?

This trial is for adults at least 18 years old with open angle glaucoma or ocular hypertension. Participants will use the study medication in one eye and a comparison drug in the other eye nightly.

Inclusion Criteria

I have been diagnosed with high eye pressure or glaucoma in both eyes.

I can attend all required study visits and cooperate with exams.

If a contact lens wearer, willing to remove contact lenses at least 24 hours prior to each of the study visits

Exclusion Criteria

Difference in IOP between eyes > 4 mmHg (unmedicated) at any baseline time point

I have narrow eye angles or a history of angle closure.

I haven't used any eye medications in the last 30 days, except for IOP drugs or dry eye drops.

What Are the Treatments Tested in This Trial?

Interventions

• Latanoprost
• Netarsudil

Trial Overview

The trial tests the effectiveness of Rocklatan (a combination of netarsudil and latanoprost) against Latanoprost alone on reducing intraocular pressure over 24 hours in patients with glaucoma or ocular hypertension.

How Is the Trial Designed?

Group I: netarsudil-latanoprost arm Experimental Treatment 1 Intervention

Group II: latanoprost arm Active Control 1 Intervention

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+

Alcon Research

Industry Sponsor

Trials

739

Recruited

128,000+

Raquel C. Bono

Alcon Research

Chief Medical Officer since 2022

MD from Harvard Medical School

David Endicott

Alcon Research

Chief Executive Officer since 2018

MBA from University of Southern California